LEXINGTON, Mass., March 7, 2018 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies and cancer vaccines, will release its
fourth quarter and full year 2017 financial results before the
market opens on Thursday, March 15,
2018. In connection with the earnings release, Agenus
executives will host a conference call and live audio webcast at
11:00 a.m. ET the same day to discuss
the results and provide a company update.
Conference Call Information:
Date: Thursday, March 15,
2018
Time: 11:00 a.m.
ET
Domestic Dial-in Number: (844) 492-3727
International Dial-in Number: (412)
317-5118
Conference ID: Agenus
Live Webcast: accessible from the Company's website
at http://investor.agenusbio.com/presentation-webcasts or with this
link https://www.webcaster4.com/Webcast/Page/1556/24878.
A replay will be available on the Company's website
approximately two hours after the call and will remain available
for 90 days.
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support early phase
clinical programs. Agenus is headquartered in Lexington,
MA. For more information, please
visit www.agenusbio.com; information that may be important to
investors will be routinely posted on our website.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding Agenus' anticipated
timing for releasing its fourth quarter and full year 2017
financial results. These forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise
the statements, other than to the extent required by
law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/agenus-to-report-fourth-quarter-and-full-year-2017-financial-results-on-march-15-2018-and-host-conference-call-and-webcast-300609359.html
SOURCE Agenus Inc.